SciELO - Scientific Electronic Library Online

SciELO - Scientific Electronic Library Online

Article References

CARMONA-FONSECA, Jaime. Recurrencias de malaria por Plasmodium vivax según el uso de primaquina: análisis de estudios descriptivos longitudinales. Rev. bras. epidemiol. [online]. 2012, vol.15, n.3, pp. 488-503. ISSN 1415-790X.  http://dx.doi.org/10.1590/S1415-790X2012000300005.

    1. WHO. World Malaria Report 2008. Geneva: WHO; 2008. [ Links ]

    2. Baird J, Leksana B, Masbar S, Fryauff D, Sutanihardja M, Suradi L et al. Diagnosis of resistance to chloroquine by Plasmodium vivax: timing of recurrence and whole blood chloroquine levels. Am J Trop Med Hyg 1997; 56: 621-6. [ Links ]

    3. Pukrittayakamee S, Vanijanonta S, Chantra A, Clemens R, White N. Blood stage antimalarial efficacy of primaquine in Plasmodium vivax malaria. Infect Dis 1994-a; 169: 932-5. [ Links ]

    4. WHO World Health Organization. Guidelines for the treatment of malaria. Documento WHO/HTM/MAL/2006.1108. Geneve: WHO; 2006. [ Links ]

    5. Vale N, Moreira R, Gomes P. Primaquine revisited six decades after its discovery. Eur J Med Chem 2009; 44: 937-53. [ Links ]

    6. Edgcomb J, Arnold J, Yount EJ, Alving A, Eichelberger L, Jeffery G et al. Primaquine, SN 13272, a new curative agent in vivax malaria: a preliminary report. J Natl Malar Soc 1950; 9: 285-92. [ Links ]

    7. Hill D, Baird J, Parise M, Lewis L, Ryan E, Magill A. Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I. Am J TropMed Hyg 2006; 75: 402-15. [ Links ]

    8. Alving A, Arnold J, Hockwald R, Clayman C, Dern R, Beutler E et al. Potentiation of the curative action of primaquine in vivax malaria by quinine and chloroquine. J Lab Clin Med 1955; 46: 301-6. [ Links ]

    9. Baird J, Hoffman S. Primaquine therapy for malaria. Clin Infect Dis 2004; 39: 1336-45. [ Links ]

    10. Baird J, Rieckmann K. Can primaquine therapy for vivax malaria be improved? Trends Parasitol 2003; 19: 115-20 [ Links ]

    11. Klein T, Tada M, Lima J, Tang A. Infection of Anopheles darlingi fed on patients infected with Plasmodium vivax before and during treatment with chloroquine plus primaquine in Costa Marques, Rondonia, Brazil. Mem Inst Oswaldo Cruz 1992; 87: 191-5. [ Links ]

    12. Duarte E, Pang L, Ribeiro L, Fontes C. Association of subtherapeutic dosages of a standard drug regimen with failures in preventing relapses of vivax malaria. Am J Trop Med Hyg 2001; 65: 471-6. [ Links ]

    13. Alving A, Johnson C, Tarlov A, Brewer G, Kellermeyer R, Carson P. Mitigation of the haemolytic effect of primaquine and enhancement of its action against exoerythrocytic forms of the Chesson strain of Plasmodium vivax by intermittent regimens of drug administration. Bull WHO 1960; 22: 621-31. [ Links ]

    14. Clyde D, McCarthy V. Radical cure of chesson strain vivax malaria in man by 7, not 14, days of treatment with primaquine. Am J Trop Med Hyg 1977; 26: 562 - 3. [ Links ]

    15. Schmidt L, Fradkin R, Vaughan D, Rasco J. Radical cure of infections with Plasmodium cynomolgi: a function of total 8-aminoquinoline dose. Am J Trop Med Hyg 1977; 26(6 pt 1): 1116-28. [ Links ]

    16. Baird J. Resistance to therapies for infection by Plasmodium vivax. Clin Microbiol Rev 2009; 22: 508-34. Review. [ Links ]

    17. Arnold J, Alving A, Clayman C, Hochwald R. Induced primaquine resistance in vivax malaria. Trans Roy Soc Trop Med Hyg 1961; 55: 345 - 50. [ Links ]

    18. Galappaththy G, Omari A, Tharyan P. Review: Primaquine for preventing relapses in people with Plasmodium vivax malaria. The Cochrane Database of systematic Reviews 2009; Issue 4. [ Links ]

    19. Carmona-Fonseca J. Malaria vivax en niños: recurrencias con dosis total estándar de primaquina dada en 3 vs. 7 días. Iatreia 2009-b; 22: 10-20. [ Links ]

    20. Primo J. Calculadora para metaanálisis [sitio de internet]. Versión actualizada en 10/7/2009; 1008,00 KB. CASP España. Unidad de Digestivo, Hospital de Sagunto. Disponible en http://www.redcaspe. org/herramientas [Consulta en 1 de julio de 2009] [ Links ]

    21. Borenstein M, Rothstin H Comprehensive Meta-Analysis 1.0.25. A computer program for research synthesis. Englewood (NJ, USA): Biostat, 1999. [ Links ]

    22. Molinero L. Meta-análisis [sitio de internet]. Asociación de la Sociedad Española de Hipertensión; Liga Epañola para la lucha contra la Hipertensión Arterial. Disponible en http://www.seh-lelha.org/metaanalisis.htm#TOP [Consulta en 5 de marzo de 2005] [ Links ]

    23. Hulley S, Cummings S, Browner W, Grady D, Hearst N, Newman T. Designing Clinical Research. 2 ed. Philadelphia: Lippincott Williams & Wilkins,2001. p. 143-74. [ Links ]

    24. Lozano J, Dennis R El experimento clínico. In: Ruiz A ML (ed). Epidemiología clínica Investigación clínica aplicada. Bogotá: Editorial Panamericana; 2004. p. 233-64. [ Links ]

    25. Abdon N, Pinto A, da-Silva RS, de-Souza J. Assessment of the response to reduced treatment schemes for vivax malaria. Rev Soc Bras Med Trop 2001; 34: 343-8. [ Links ]

    26. Adak T, Sharma V, Orlov V. Studies on the Plasmodium vivax relapse pattern in Delhi, India. Am J Trop Med Hyg 1998; 59: 175-9. [ Links ]

    27. Alving A, Hankey D, Coatney G, Jones RJ, Coker W, Garrison P et al. Korean vivax malaria. II. Curative treatment with pamaquine and primaquine. Am J Trop Med Hyg 1953; 6: 970-6. [ Links ]

    28. Coatney G, Alving A, Jones RJ, Hankey D, Robinson D, PL. G. et al. Korean vivax malaria. V. Cure of the infection by primaquine administered during long-term latency. Am J Trop Med Hyg 1953; 2: 985 - 8. [ Links ]

    29. Hankey D, Jones JR, Coatney G, Aving A, Coker W, Garrison P et al. Korean vivax malaria. I. Natural history and response to chloroquine. Am J Trop Med 1953; 2: 958-69. [ Links ]

    30. Awab G, Pukrittayakamee S, Imwong M, Dondorp A, Woodrow C, Lee S et al. Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial. Malar J 2010; 9: 105. [ Links ]

    31. Boulos M, Amato-Neto V, Dutra A, Di Santi S, Shiroma M. [Frequency of malaria relapse due to P. vivax in a non-endemic region (São Paulo, Brazil)][Portuguese]. Rev Inst Med Trop Sao Paulo 1991; 33: 143-6. [ Links ]

    32. Carmona-Fonseca J, Maestre A. Prevention of Plasmodium vivax malaria recurrence: Efficacy of the standard total dose of primaquine administered over 3 days. Acta Tropica 2009-a; 112: 188-92. [ Links ]

    33. Dua V, Sharma V. Plasmodium vivax relapses after 5 days of primaquine treatment, in some industrial complexes of India. Ann Trop Med Parasitol 2001; 95: 655-9. [ Links ]

    34. Fairley N. Chemotherapeutic suppression and prophylaxis in malaria. Trans Roy Soc Trop Med Hyg 1945; 38: 311 - 57. [ Links ]

    35. Fernandopulle B, Weeraratne C, Weerasuriya K, Karunaweera N. Efficacy of a five-day course of primaquine in preventing relapses in Plasmodium vivax malaria - a pilot study. Ceylon Med J 2003; 48: 32. [ Links ]

    36. Fryauff D, Baird J, Purnomo Awalludin M, Jones T, Subianto B, Richie T, et al. Malaria in a nonimmune population after extended chloroquine or primaquine prophylaxis. Am J Trop Med Hyg 1997; 56: 137-40. [ Links ]

    37. Gogtay N, Garg M, Kadam V, Kamtekar K, Kshirsagar N. A 5 days primaquine regimen as anti-relapse therapy for Plasmodium vivax. Trans R Soc Trop Med Hyg 1998; 92: 341. Comment in: Trans R Soc Trop Med Hyg 1998; 1992(1996): 1687. [ Links ]

    38. Gogtay N, Desai S, Kadam V, Kamtekar K, Dalvi S, Kshirsagar N. Relapse pattern of Plasmodium vivax in Mumbai: a study of 283 cases of vivax malaria. J Assoc Physicians India 2000; 48: 1085-6. Comment in: J Assoc Physicians India 2002; 1050:1458-99. [ Links ]

    39. Hanf M, Stéphani A, Basurko C, Nacher M, Carme B. Determination of the Plasmodium vivax relapse pattern in Camopi, French Guiana. Malar J 2009; 8: 278. [ Links ]

    40. Jelinek T, Nothdurft H, Von Sonnenburg F, Loscher T. Long-term efficacy of primaquine in the treatment of vivax malaria in nonimmune travelers. Am J Trop Med Hyg 1995; 52: 322-4. [ Links ]

    41. Leslie T, Rab M, Ahmadzai H, Durrani N, Fayaz M, Kolaczinski J, et al. Compliance with 14-day primaquine therapy for radical cure of vivax malaria: a randomized placebo-controlled trial comparing unsupervised with supervised treatment. Trans R Soc Trop Med Hyg 2004; 98: 168-73. [ Links ]

    42. Luxemburger C, van Vugt M, Jonathan S, McGready R, Looareesuwan S, White N, et al. Treatment of vivax malaria on the western border of Thailand. Trans R Soc Trop Med Hyg 1999; 93: 433-8. [ Links ]

    43. Maneeboonyang W, Lawpoolsri S, Puangsa-Art S, Yimsamran S, Thanyavanich N, Wuthisen P et al. Directly observed therapy with primaquine to reduce the recurrence rate of plasmodium vivax infection along the Thai-Myanmar border. Southeast Asian J Trop Med Public Health 2011; 42: 9-18. [ Links ]

    44. Moon K, Kim Y, Ko D, Park I, Shin D, Kim C. Recurrence rate of vivax malaria in the Republic of Korea. Trans R Soc Trop Med Hyg 2009; 103: 1245-9. [ Links ]

    45. Orjuela-Sánchez P, de Santana Filho F, Machado-Lima A, Chehuan Y, Costa M, Alecrim M, et al. Analysis of single-nucleotide polymorphisms in the crt-o and mdr1 genes of Plasmodium vivax among chloroquine-resistant isolates from the Brazilian Amazon region. Antimicrob Agents Chemother 2009; 53: 3561-4. [ Links ]

    46. Rowland M, Durrani N. Randomized controlled trials of 5-and 14-days primaquine therapy against relapses of vivax malaria in an Afghan refugee settlement in Pakistan. Trans R SocTrop Med Hyg 1999; 93: 641 - 3. [ Links ]

    47. Schwartz E, Sidi Y. New aspects of malaria imported from Ethiopia. Clin Infect Dis 1998; 26: 1089-91. [ Links ]

    48. Schwartz E, Regev-Yochay G, Kurnik D. Short report: a consideration of primaquine dose adjustment for radical cure of Plasmodium vivax malaria. Am J Trop Med Hyg 2000; 62: 393-395. [ Links ]

    49. Sharma R, Gautam A, Orlov V, Sharma V. Relapse pattern of Plasmodium vivax in Kheda district, Gujarat. Indian J Malariol 1990; 27: 95-9. [ Links ]

    50. Singh N, Mishra A, Sharma V. Radical treatment of vivax malaria in Madhya Pradesh, India. Indian J Malariol 1990; 27: 55-6. [ Links ]

    51. Sinha S, Dua V, Sharma V. Efficacy of 5 day radical treatment of primaquine in Plasmodium vivax cases at the BHEL industrial complex, Hardwar (U.P.). Indian J Malariol 1989; 26: 83-6. [ Links ]

    52. Sinha S, Dua V, Sharma V. Malaria relapses and chloroquine resistance at the BHEL industrial complex, Hardwar, India. Trans R Soc Trop Med Hyg 1989; 83: 606. [ Links ]

    53. Smoak B, DeFraites R, Magill A, Kain K, Wellde B. Plasmodium vivax infections in U.S. Army troops: failure of primaquine to prevent relapse in studies from Somalia. Am J Trop Med Hyg 1997; 56: 231-4. [ Links ]

    54. Solari-Soto L, Soto-Tarazona A, D. M-R, Llanos-Cuentas A. Ensayo clínico del tratamiento de la malaria vivax con esquema acortado de primaquina comparado con el esquema tradicional. Rev Soc Peru Med Interna 2002; 15: 196-9. [ Links ]

    55. Srivastava H, Sharma S, Bhatt R, Sharma V. Studies on Plasmodium vivax relapse pattern in Kheda district, Gujarat. Indian J Malariol 1996; 33: 173-9. [ Links ]

    56. Takeuchi R, Lawpoolsri S, Imwong M, Kobayashi J, Kaewkungwal J, Pukrittayakamee S, et al. Directly-observed therapy (DOT) for the radical 14-day primaquine treatment of Plasmodium vivax malaria on the Thai-Myanmar border. Malar J 2010; 9: 308. [ Links ]

    57. Villalobos-Salcedo J, Tada M, Kimura E, Menezes M, Pereira da Silva L. In-vivo sensitivity of Plasmodium vivax isolates from Rondonia (western Amazon region, Brazil) to regimens including chloroquine and primaquine. Ann Trop Med Parasitol 2000; 94: 749-58. [ Links ]

    58. da Silva R, Pinto A, Calvosa V, de Souza J. Esquemas terapêuticos encurtados para o tratamento de malária por Plasmodium vivax. Short course schemes for vivax malaria treatment. Rev Soc Bras Med Trop 2003; 36: 235-9. [ Links ]

    59. Pinto A, Ventura A, Calvosa V, Silva-Filho M, Santos M, Silva R, et al. Eficácia de quatro esquemas terapêuticos para malaria vivax em crianças. J Pediatr 1998; 74: 222-7. [ Links ]

    60. Goller J, Jolley D, Ringwald P, Biggs B. Regional differences in the response of plasmodium vivax malaria to primaquine as anti-relapse therapy. Am J Trop Med Hyg 2007; 76: 203-7. [ Links ]

    61. Kshirsagar N. Malaria: anti malarial resistance and policy ramifications and challenges. J Postgrad Med 2006; 52: 291 - 3. [ Links ]

    62. Garnham P. Hypnozoites and "relapses" in Plasmodium vivax and in vivax-like malaria. Trop Geogr Med 1988; 40: 187-95. [ Links ]

    63. Joshi H, Prajapati S, Verma A, Kang'a S, Carlton J. Plasmodium vivax in India. Trends Parasitol 2008; 24: 228-35. [ Links ]

    64. Santos J, Luz F, Deckers F, Tauil P. Subdoses of primaquine in overweight patients and malaria vivax relapses: report of two cases in the Federal District, Brazil. Rev Soc Bras Med Trop 2010; 43: 749-50. [ Links ]

    65. Carmona-Fonseca J. Profilaxis primaria con primaria para el paludismo. Revisión. Anuario de Enfermedades Infecciosas (Medellín) 2005; 2: 51-84. [ Links ]

    66. Carmona-Fonseca J. La primaquina tiene alta eficacia en la quimioprofilaxis primaria simple antipalúdica. Metanálisis. Iatreia 2006; 19: 244-60. [ Links ]

    67. Nogueira F, Moreira-Campos L, Santos R, Pianetti G. Quality of essential drugs in tropical countries: evaluation of antimalarial drugs in the Brazilian Health System. Rev Soc Bras Med Trop 2011; 44: 582-6. [ Links ]

    68. Newton P, Fernandez F, Plancon A, Mildenhall D, Green M, al e. A collaborative epidemiological investigation into the criminal fake artesunate trade in South East Asia. PLoS Med 2008; 5(2): e32. [ Links ]

    69. Bate R, Coticelli P, Tren R, Attaran A. Antimalarial drug quality in the most severely malarious parts of Africa - A six country study. PLoS ONE 2008; 3(5):e2132. [ Links ]

    70. Arias F. Convenio con Invima contra el tráfico de medicamentos en Colombia. El Colombiano (periódico) Medellín, Colombia, 9 de noviembre de 2004. [ Links ]

    71. Ferreira M, Gomes MdS, Vieira J. [Methemoglobinemia in patients with Plasmodium vivax receiving oral therapy with primaquine] [en Portugués]. Rev Soc Bras Med Trop 2011; 44: 113-5. [ Links ]

    72. Youngster I, Arcavi L, Schechmaster R, Akayzen Y, Popliski H, Shimonov J et al. Medications and glucose-6-phosphate dehydrogenase deficiency: an evidence-based review. Drug Saf 2010; 33: 713-26. [ Links ]

    73. Carmona-Fonseca J, Alvarez G, Maestre A. Methemoglobinemia and adverse events in Plasmodium vivax malaria patients associated with high doses of primaquine treatment. Am J Trop Med Hyg 2009-c; 80: 188-93. [ Links ]

    74. Tekwani B, Walker L. 8-Aminoquinolines: future role as antiprotozoal drugs. Curr Opin Infect Dis 2006; 19: 623-31. [ Links ]

    75. Crockett M, Kain K. Crockett M, Kain KC. Tafenoquine: a promising new antimalarial agent. Expert Opin Investig Drugs. 2007; 16(5):705-15. Expert Opin Investig Drugs 2007; 16: 705-15. [ Links ]

    76. Manzano J, Carvalho L, García-Hernández R, Poveda J, Ferragut J, Castanys S, et al. Uptake of the antileishmania drug tafenoquine follows a sterol-dependent diffusion process in Leishmania. J Antimicrob Chemother 2011; 66: 2562-5. [ Links ]

    77. Shiraki H, Kozar M, Melendez V, Hudson T, Ohrt C, Magill A, et al. Antimalarial activity of novel 5-aryl-8-aminoquinoline derivatives. J Med Chem 2011; 54: 131-42. [ Links ]

    78. Charles B, Miller A, Nasveld P, Reid M, Harris I, Edstein M. Population pharmacokinetics of tafenoquine during malaria prophylaxis in healthy subjects. Antimicrob Agents Chemother 2007; 51: 2709-15. [ Links ]